SYS-CON MEDIA Authors: Peter Silva, Kevin Jackson, Jessica Qiu, Dana Gardner, Dan Stolts

News Feed Item

Trends in Therapeutic Partnering

LONDON, Aug. 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Trends in Therapeutic Partnering

https://www.reportbuyer.com/product/1593890/Trends-in-Therapeutic-Partnering.html

The Trends in Therapeutic Partnering report provides the most comprehensive and in-depth insight into the 35 most popular therapeutic targets for partnering in the period 2009 to mid 2014.

The report provides a detailed understanding and analysis of the most popular therapeutic targets for partnering in the period 2009 to mid 2014. The majority of deals are discovery, preclinical and clinical stage whereby the licensee obtains a right or an option right to license or access the licensors compounds or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapeutic targets. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 300 charts allow quick understanding of therapeutic partnering trends since 2007, together with insight into which companies are active in each of the thirty five leading therapeutic areas.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of therapeutic dealmaking.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of therapeutic dealmaking since 2009, listing the top therapeutic areas for partnering by deal frequency and deal dollars committed by partnering companies.

Chapter 3 reviews the top pharma and biotech therapeutic partnering deals of 2009-2014 according to reported deal size.

Chapter 4 provides a summary on best practice on how to submit an opportunity to the leading therapeutic partnering companies, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 5 lists forthcoming partnering events where valuable face to face meetings with biopharma companies provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 6. In-depth profiles of each of the top 35 therapeutic target areas according to deal frequency during the period 2009-2014 provide everything required to assess the potential of the therapeutic area and its active partner companies. Each profile includes a partnering activity overview, deal financials (including headline, upfront and royalties rates, where available).

Each therapeutic profile provides a listing of partnering deals for the top fifiteen most active companies in each therapeutic area, and is accompanied by an appendix that provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negiotated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This data driven report contains over 5,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In addition, contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to understand trends in therapeutic partnering, the most active therapeutic areas in terms of deal frequency and leading deal maker companies, and the deal terms and structures achieved in such therapeutic partnering deals.

Report scope


Trends in Therapeutic Partnering is intended to provide the reader with an in-depth understanding of therapeutic partnering trends and structure of deals entered into by leading companies worldwide.


Trends in Therapeutic Partnering includes:

Trends in therapeutic dealmaking in the biopharma industry since 2009
Analysis of therapeutic partnering deal structure
Access to over 5,000 therapeutic partnering deals
The top 35 therapeutic targets for partnering since 2009
The leading therapeutic partnering deals by value since 2009
Most active therapeutic partnering dealmakers since 2009

In Trends in Therapeutic Partnering, the available deals are listed by:

Most active companies in partnering for each therapeutic area
Headline value
Upfront payment
Royalty rate
Company A-Z

Each deal title links to online deal records of actual therapeutic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The Trends in Therapeutic Partnering report provides comprehensive access to available deal records for over 5,000 therapeutic target partnering deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in therapeutic dealmaking activity

2.1. Introduction
2.2. Leading therapy partnering areas
2.3. Top therapeutic targets for partnering 2009-2014

Chapter 3 – Leading therapy deals by value
3.1. Introduction
3.2. Big pharma therapy partnering
3.3. Big biotech therapy partnering

Chapter 4 – Submitting opportunities to therapeutic target partner companies

4.1. How to submit an opportunity
4.2. Opportunity submission template
4.3. Sending emails
4.4. Face to face at partnering events
4.5. Online submission forms
Chapter 5 – Forthcoming therapeutic partnering events
5.1. Forthcoming events

Chapter 6 – Top 35 therapeutic partnering targets

6.1. Introduction
6.2. Therapeutic profiles
1. Diabetes
Diabetes partnering in numbers
Top diabetes partnering deals by value
Most active diabetes partnering companies
2. Pain CNS
Pain partnering in numbers
Top pain partnering deals by value
Most active pain partnering companies
3. Breast cancer
Breast cancer partnering in numbers
Top breast cancer partnering deals by value
Most active breast cancer partnering companies
4. Alzheimer's disease
Alzheimer's disease partnering in numbers
Top Alzheimer's disease partnering deals by value
Most active Alzheimer's disease partnering companies
5. Lung cancer
Lung cancer partnering in numbers
Top lung cancer partnering deals by value
Most active lung cancer partnering companies
6. Wound healing
Wound healing partnering in numbers
Top wound healing partnering deals by value
Most active wound healing partnering companies
7. HIV
HIV partnering in numbers
Top HIV partnering deals by value
Most active HIV partnering companies
8. Inflammation
Inflammation partnering in numbers
Top Inflammation partnering deals by value
Most active inflammation partnering companies
9. Influenza
Influenza partnering in numbers
Top influenza partnering deals by value
Most active influenza partnering companies
10. Prostate cancer
Prostate cancer partnering in numbers
Top prostate cancer partnering deals by value
Most active prostate cancer partnering companies
11. Leukemia
Leukemia partnering in numbers
Top leukemia partnering deals by value
Most active leukemia partnering companies
12. Nutrition & Vitamins
Nutrition & Vitamins partnering in numbers
Top nutrition & vitamins partnering deals by value
Most active nutrition & vitamin partnering companies
13. Solid tumor
Solid tumor partnering in numbers
Top solid tumors partnering deals by value
Most active solid tumor partnering companies
14. Parkinson's disease
Parkinson's disease partnering in numbers
Top Parkinson's disease partnering deals by value
Most active Parkinson's disease partnering companies
15. Colorectal cancer
Colorectal cancer partnering in numbers
Top colorectal cancer partnering deals by value
Most active colorectal cancer partnering companies
16. Rheumatoid arthritis
Rheumatoid arthritis partnering in numbers
Top rheumatoid arthritis partnering deals by value
Most active rheumatoid arthritis partnering companies
17. Multiple sclerosis
Multiple sclerosis partnering in numbers
Top multiple sclerosis partnering deals by value
Most active multiple sclerosis partnering companies
18. Orthopedics
Orthopedics partnering in numbers
Top Orthopedics partnering deals by value
Most active Orthopedics partnering companies
19. Accident & emergency
Accident & emergency partnering in numbers
Top Accident & emergency partnering deals by value
Most active accident & emergency partnering companies
20. Hepatitis C
Hepatitis C partnering in numbers
Top hepatitis C partnering deals by value
Most active hepatitis C partnering companies
21. Transplantation
Transplantation partnering in numbers
Top transplantation partnering deals by value
Most active transplantation partnering companies
22. Obesity
Obesity partnering in numbers
Top obesity partnering deals by value
Most active obesity partnering companies
23. Ovarian cancer
Ovarian cancer partnering in numbers
Top ovarian cancer partnering deals by value
Most active ovarian cancer partnering companies
24. Lymphoma
Lymphoma partnering in numbers
Top lymphoma partnering deals by value
Most active lymphoma partnering companies
25. Tuberculosis
Tuberculosis partnering in numbers
Top tuberculosis partnering deals by value
Most active tuberculosis partnering companies
26. Spinal cord
Spinal cord partnering in numbers
Top spinal cord partnering deals by value
Most active spinal cord partnering companies
27. Pancreatic cancer
Pancreatic cancer partnering in numbers
Top pancreatic cancer partnering deals by value
Most active pancreatic cancer partnering companies
28. Cosmetics
Cosmetics partnering in numbers
Top cosmetics partnering deals by value
Most active cosmetics partnering companies
29. Asthma
Asthma partnering in numbers
Top asthma partnering deals by value
Most active asthma partnering companies
30. Congestive heart failure
Congestive heart failure partnering in numbers
Top congestive heart failure partnering deals by value
Most active congestive heart failure partnering companies
31. Rare Genetics Disorders
Rare Genetics Disorders partnering in numbers
Top rare genetic disorders partnering deals by value
Most active rare genetic disorders partnering companies
32. Malaria
Malaria partnering in numbers
Top malaria partnering deals by value
Most active malaria partnering companies
33. Melanoma
Melanoma partnering in numbers
Top melanoma partnering deals by value
Most active melanoma partnering companies
34. Brain cancer
Brain cancer partnering in numbers
Top brain cancer partnering deals by value
Most active brain cancer partnering companies
35. Stroke
Stroke partnering in numbers
Top stroke partnering deals by value
Most active stroke partnering companies

Chapter 7 – Resources

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Deal Type Reports
Order Form – Technology Reports
Order Form – Therapy Reports
Order Form – Upgrades to subscription access products

See 3 separate volumes for the following appendices

Appendix volume 1
Appendix 1 – Diabetes deal directory – company A-Z
Appendix 2 – Pain deal directory – company A-Z
Appendix 3 – Breast cancer deal directory – company A-Z
Appendix 4 – Alzeimer's disease deal directory – company A-Z
Appendix 5 – Lung cancer deal directory – company A-Z
Appendix 6 –Wound healing deal directory – company A-Z
Appendix 7 – HIV deal directory – company A-Z
Appendix 8 –Inflammation deal directory – company A-Z
Appendix 9 –Influenza deal directory – company A-Z

Appendix volume 2
Appendix 10 – Prostate cancer deal directory – company A-Z
Appendix 11 – Leukemia deal directory – company A-Z
Appendix 12 – Nutrition & Vitamins deal directory – company A-Z
Appendix 13 – Solid tumors deal directory – company A-Z
Appendix 14 – Parkinson's disease deal directory – company A-Z
Appendix 15 – Colorectal cancer deal directory – company A-Z
Appendix 16 – Rheumatoid arthritis deal directory – company A-Z
Appendix 17 –Multiple sclerosis deal directory – company A-Z
Appendix 18 –Orthopedics deal directory – company A-Z
Appendix 19 – Accident & emergency deal directory – company A-Z
Appendix 20 – Hepatitis C deal directory – company A-Z
Appendix 21 – Transplantation deal directory – company A-Z
Appendix 22 –Obesity deal directory – company A-Z
Appendix 23 – Ovarian cancer deal directory – company A-Z

Appendix volume 3
Appendix 24 – Lymphoma deal directory – company A-Z
Appendix 25 – Tuberculosis deal directory – company A-Z
Appendix 26 – Spinal cord deal directory – company A-Z
Appendix 27 – Pancreatic cancer deal directory – company A-Z
Appendix 28 – Cosmetics deal directory – company A-Z
Appendix 29 – Asthma deal directory – company A-Z
Appendix 30 – Congestive heart failure deal directory – company A-Z
Appendix 31 – Rare genetic disorders deal directory – company A-Z
Appendix 32 – Malaria deal directory – company A-Z
Appendix 33 – Melanoma deal directory – company A-Z
Appendix 34 – Brain cancer deal directory – company A-Z
Appendix 35 – Stroke deal directory – company A-Z
Appendix 36 – Deal type definitions
Appendix 37 – Example contract document

TABLE OF FIGURES

Figure 1: Partnering trends by therapy area 2009-2014
Figure 2: Top most partnered therapeutics targets 2009-2014
Figure 3: Top partnered therapeutic targets by financial value 2009-2014
Figure 4: Leading big pharma therapy partnering deals by value, 2009-2014
Figure 5: Leading big biotech therapy partnering deals by value, 2009-2014
Figure 6: Typical partnering opportunity submission template
Figure 7: Diabetes: Partnering frequency 2009-2014
Figure 8: Diabetes: most active dealmakers
Figure 9: Diabetes: partnering deals by sector
Figure 10: Diabetes partnering deals by type
Figure 11: Diabetes partnering deals by technology type
Figure 12: Diabetes artnering deals by stage of development
Figure 13: Diabetes partnering deals by headline value
Figure 14: Diabetes: partnering deals by upfront payment
Figure 15: Diabetes partnering deals by royalty rate
Figure 16: Diabetes: partnering deals 2009-2014 – most active companies
Figure 17: Pain: Partnering frequency 2009-2014
Figure 18: Pain partnering most active dealmakers
Figure 19: Pain partnering deals by sector
Figure 20: Pain partnering deals by type
Figure 21: Pain partnering deals by technology type
Figure 22: Pain partnering deals by stage of development
Figure 23: Pain partnering deals by headline value
Figure 24: Pain partnering deals by upfront payment
Figure 25: Pain partnering deals by royalty rate
Figure 26: Pain partnering deals 2009-2014 by most active companies
Figure 27: Breast cancer: Partnering frequency 2009-2014
Figure 28: Breast cancer most active dealmakers
Figure 29: Breast cancer partnering deals by sector
Figure 30: Breast cancer partnering deals by type
Figure 31: Breast cancer partnering deals by technology type
Figure 32: Breast cancer partnering deals by stage of development
Figure 33: Breast cancer partnering deals by headline value
Figure 34: Breast cancer partnering deals by upfront payment
Figure 35: Breast cancer partnering deals by royalty rate
Figure 36: Breast cancer partnering deals 2009-2014 by most active companies
Figure 37: Alzheimer's disease: Partnering frequency 2009-2014
Figure 38: Alzheimer's disease most active dealmakers
Figure 39: Alzheimer's disease partnering deals by sector
Figure 40: Alzheimer's disease partnering deals by type
Figure 41: Alzheimer's disease partnering deals by technology type
Figure 42: Alzheimer's disease partnering deals by stage of development
Figure 43: Alzheimer's disease partnering deals by headline value
Figure 44: Alzheimer's disease partnering deals by upfront payment
Figure 45: Alzheimer's disease partnering deals by royalty rate
Figure 46: Alzheimer's partnering deals 2009-2014 by most active companies
Figure 47: Lung cancer: Partnering frequency 2009-2014
Figure 48: Lung cancer most active dealmakers
Figure 49: Lung cancer partnering deals by sector
Figure 50: Lung cancer partnering deals by type
Figure 51: Lung cancer partnering deals by technology type
Figure 52: Lung cancer partnering deals by stage of development
Figure 53: Lung cancer partnering deals by headline value
Figure 54: Lung cancer partnering deals by upfront payment
Figure 55: Lung cancer partnering deals by royalty rate
Figure 56: Lung cancer partnering deals 2009-2014 by most active companies
Figure 57: Wound healing: Partnering frequency 2009-2014
Figure 58: Wound healing most active dealmakers
Figure 59: Wound healing partnering deals by sector
Figure 60: Wound healing partnering deals by type
Figure 61: Wound healing partnering deals by technology type
Figure 62: Wound healing partnering deals by stage of development
Figure 63: Wound healing partnering deals by headline value
Figure 64: Wound healing partnering deals by upfront payment
Figure 65: Wound healing partnering deals by royalty rate
Figure 66: Wound healing partnering deals 2009-2014 by most active companies
Figure 67: HIV: Partnering frequency 2009-2014
Figure 68: HIV most active dealmakers
Figure 69: HIV partnering deals by sector
Figure 70: HIV partnering deals by type
Figure 71: HIV partnering deals by technology type
Figure 72: HIV partnering deals by stage of development
Figure 73: HIV partnering deals by headline value
Figure 74: HIV partnering deals by upfront payment
Figure 75: HIV partnering deals by royalty rate
Figure 76: HIV partnering deals 2009-2014 by most active companies
Figure 77: Inflammation: Partnering frequency 2009-2014
Figure 78: Inflammation most active dealmakers
Figure 79: Inflammation partnering deals by industry sector
Figure 80: Inflammation partnering deals by type
Figure 81: Inflammation partnering deals by technology type
Figure 82: Inflammation partnering deals by stage of development
Figure 83: Inflammation partnering deals by headline value
Figure 84: Inflammation partnering deals by upfront payment
Figure 85: Inflammation partnering deals by royalty rate
Figure 86: Inflammation partnering deals 2009-2014 by most active companies
Figure 87: Influenza: Partnering frequency 2009-2014
Figure 88: Influenza most active dealmakers
Figure 89: Influenza partnering deals by industry sector
Figure 90: Influenza partnering deals by type
Figure 91: Influenza partnering deals by technology type
Figure 92: Influenza partnering deals by stage of development
Figure 93: Influenza partnering deals by headline value
Figure 94: Influenza partnering deals by upfront payment
Figure 95: Influenza partnering deals by royalty rate
Figure 96: Influenza partnering deals 2009-2014 by most active companies
Figure 97: Prostate cancer: Partnering frequency 2009-2014
Figure 98: Prostate cancer most active dealmakers
Figure 99: Prostate cancer partnering deals by industry sector
Figure 100: Prostate cancer partnering deals by type
Figure 101: Prostate cancer partnering deals by technology type
Figure 102: Prostate cancer partnering deals by stage of development
Figure 103: Prostate cancer partnering deals by headline value
Figure 104: Prostate cancer partnering deals by upfront payment
Figure 105: Prostate cancer partnering deals by royalty rate
Figure 106: Prostate cancer partnering deals 2009-2014 by most active companies
Figure 107: Leukemia: Partnering frequency 2009-2014
Figure 108: Leukemia most active dealmakers
Figure 109: Leukemia partnering deals by industry sector
Figure 110: Leukemia partnering deals by type
Figure 111: Leukemia partnering deals by technology type
Figure 112: Leukemia partnering deals by stage of development
Figure 113: Leukemia partnering deals by headline value
Figure 114: Leukemia partnering deals by upfront payment
Figure 115: Leukemia partnering deals by royalty rate
Figure 116: Leukemia partnering deals 2009-2014 by most active companies
Figure 117: Nutrition & Vitamins: Partnering frequency 2009-2014
Figure 118: Nutrition & Vitamins most active dealmakers
Figure 119: Nutrition & Vitamins partnering deals by sector
Figure 120: Nutrition & Vitamins partnering deals by type
Figure 121: Nutrition & Vitamins partnering deals by technology type
Figure 122: Nutrition & Vitamins partnering deals by stage of development
Figure 123: Nutrition & Vitamins partnering deals by headline value
Figure 124: Nutrition & Vitamins partnering deals by upfront payment
Figure 125: Nutrition & Vitamins partnering deals by royalty rate
Figure 126: Nutrition & Vitamins partnering deals 2009-2014 by most active companies
Figure 127: Solid tumor: Partnering frequency 2009-2014
Figure 128: Solid tumor most active dealmakers
Figure 129: Solid tumor partnering deals by industry sector
Figure 130: Solid tumor partnering deals by type
Figure 131: Soid tumor partnering deals by technology type
Figure 132: Solid tumor partnering deals by stage of development
Figure 133: Solid tumor partnering deals by headline value
Figure 134: Solid tumor partnering deals by upfront payment
Figure 135: Solid tumor partnering deals by royalty rate
Figure 136: Solid tumor partnering deals 2009-2014 by most active companies
Figure 137: Parkinson's disease: Partnering frequency 2009-2014
Figure 138: Parkinson's disease most active dealmakers
Figure 139: Parkinson's disease partnering deals by industry sector
Figure 140: Parkinson's disease partnering deals by type
Figure 141: Parkinson's disease partnering deals by technology type
Figure 142: Parkinson's disease partnering deals by stage of development
Figure 143: Parkinson's disease partnering deals by headline value
Figure 144: Parkinson's disease partnering deals by upfront payment
Figure 145: Parkinson's disease partnering deals by royalty rate
Figure 146: Parkinson's disease partnering deals 2009-2014 by most active companies
Figure 147: Colorectal cancer: Partnering frequency 2009-2014
Figure 148: Colorectal cancer most active dealmakers
Figure 149: Colorectal cancer partnering deals by industry sector
Figure 150: Colorectal cancer partnering deals by type
Figure 151: Colorectal cancer partnering deals by technology type
Figure 152: Colorectal cancer partnering deals by stage of development
Figure 153: Colorectal cancer partnering deals by headline value
Figure 154: Coloretal cancer partnering deals by upfront payment
Figure 155: Colorectal cancer partnering deals by royalty rate
Figure 156: Colorectal cancer partnering deals 2009-2014 by most active companies
Figure 157: Rheumatoid arthritis: Partnering frequency 2009-2014
Figure 158: Rheumatoid arthritis most active dealmakers
Figure 159: Rheumatoid arthritis partnering deals by industry sector
Figure 160: Rheumatoid arthritis partnering deals by type
Figure 161: Rheumatoid arthritis partnering deals by technology type
Figure 162: Rheumatoid arthritis partnering deals by stage of development
Figure 163: Rheumatoid arthritis partnering deals by headline value
Figure 164: Rheumatoid arthritis partnering deals by upfront payment
Figure 165: Rheumatoid arthritis partnering deals by royalty rate
Figure 166: Rheumatoid arthritis partnering deals 2009-2014 by most active companies
Figure 167: Multiple sclerosis: Partnering frequency 2009-2014
Figure 168: Multiple sclerosis most active dealmakers
Figure 169: Multiple sclerosis partnering deals by industry sector
Figure 170: Multiple sclerosis partnering deals by type
Figure 171: Multiple sclerosis partnering deals by technology type
Figure 172: Multiple sclerosis partnering deals by stage of development
Figure 173: Multiple sclerosis partnering deals by headline value
Figure 174: Multiple sclerosis partnering deals by upfront payment
Figure 175: Multiple sclerosis partnering deals by royalty rate
Figure 176: Multiple sclerosis partnering deals 2009-2014 by most active companies
Figure 177: Orthopedics: Partnering frequency 2009-2014
Figure 178: Orthopedics most active dealmakers
Figure 179: Orthopedics partnering deals by industry sector
Figure 180: Orthopedics partnering deals by type
Figure 181: Orthopedics partnering deals by technology type
Figure 182: Orthopedics partnering deals by stage of development
Figure 183: Orthopedics partnering deals by headline value
Figure 184: Orthopedics partnering deals by upfront payment
Figure 185: Orthopedics partnering deals by royalty rate
Figure 186: Orthopedics partnering deals 2009-2014 by most active companies
Figure 187: Accident & emergency: Partnering frequency 2009-2014
Figure 188: Accident & emergency most active dealmakers
Figure 189: Accident & emergency partnering deals by industry sector
Figure 190: Accident & emergency partnering deals by type
Figure 191: Accident & emergency partnering deals by technology type
Figure 192: Accident & emergency partnering deals by stage of development
Figure 193: Accident & emergency partnering deals by headline value
Figure 194: Accident & emergency partnering deals by upfront payment
Figure 195: Accident & emergency partnering deals by royalty rate
Figure 196: Accident & emergency partnering deals 2009-2014 by most active companies
Figure 197: Hepatitis C: Partnering frequency 2009-2014
Figure 198: Hepatitis C most active dealmakers
Figure 199: Hepatitis C partnering deals by industry sector
Figure 200: Hepatitis C partnering deals by type
Figure 201: Hepatitis C partnering deals by technology type
Figure 202: Hepatitis C partnering deals by stage of development
Figure 203: Hepatitis C partnering deals by headline value
Figure 204: Hepatitis C partnering deals by upfront payment
Figure 205: Hepatitis C partnering deals by royalty rate
Figure 206: Hepatitis C partnering deals 2009-2014 by most active companies
Figure 207: Transplantation: Partnering frequency 2009-2014
Figure 208: Transplantation most active dealmakers
Figure 209: Transplantation partnering deals by industry sector
Figure 210: Transplantation partnering deals by type
Figure 211: Transplantation partnering deals by technology type
Figure 212: Transplantation partnering deals by stage of development
Figure 213: Transplantation partnering deals by headline value
Figure 214: Transplantation partnering deals by upfront payment
Figure 215: Transplantation partnering deals by royalty rate
Figure 216: Transplantation partnering deals 2009-2014 by most active companies
Figure 217: Obesity: Partnering frequency 2009-2014
Figure 218: Obesity most active dealmakers
Figure 219: Obesity partnering deals by industry sector
Figure 220: Obesity partnering deals by type
Figure 221: Obesity partnering deals by technology type
Figure 222: Obesity partnering deals by stage of development
Figure 223: Obesity partnering deals by headline value
Figure 224: Obesity partnering deals by upfront payment
Figure 225: Obesity partnering deals by royalty rate
Figure 226: Obesity partnering deals 2009-2014 by most active companies
Figure 227: Ovarian cancer: Partnering frequency 2009-2014
Figure 228: Ovarian cancer most active dealmakers
Figure 229: Ovarian cancer partnering deals by industry sector
Figure 230: Ovarian cancer partnering deals by type
Figure 231: Ovarian cancer partnering deals by technology type
Figure 232: Ovarian cancer partnering deals by stage of development
Figure 233: Ovarian cancer partnering deals by headline value
Figure 234: Ovarian cancer partnering deals by upfront payment
Figure 235: Ovarian cancer partnering deals by royalty rate
Figure 236: Ovarian cancer partnering deals 2009-2014 by most active companies
Figure 237: Lymphoma: Partnering frequency 2009-2014
Figure 238: Lymphoma most active dealmakers
Figure 239: Lymphoma partnering deals by industry sector
Figure 240: Lymphoma partnering deals by type
Figure 241: Lymphoma partnering deals by technology type
Figure 242: Lymphoma partnering deals by stage of development
Figure 243: Lymphoma partnering deals by headline value
Figure 244: Lymphoma partnering deals by upfront payment
Figure 245: Lymphoma partnering deals by royalty rate
Figure 246: Lymphoma partnering deals 2009-2014 by most active companies
Figure 247: Tuberculosis: Partnering frequency 2009-2014
Figure 248: Tuberculosis most active dealmakers
Figure 249: Tuberculosis partnering deals by industry sector
Figure 250: Tuberculosis partnering deals by type
Figure 251: Tuberculosis partnering deals by technology type
Figure 252: Tuberculosis partnering deals by stage of development
Figure 253: Tuberculosis partnering deals by headline value
Figure 254: Tuberculosis partnering deals by upfront payment
Figure 255: Tuberculosis partnering deals by royalty rate
Figure 256: Tuberculosis partnering deals 2009-2014 by most active companies
Figure 257: Spinal cord: Partnering frequency 2009-2014
Figure 258: Spinal cord most active dealmakers
Figure 259: Spinal cord partnering deals by industry sector
Figure 260: Spinal cord partnering deals by type
Figure 261: Spinal cord partnering deals by technology type
Figure 262: Spinal cord partnering deals by stage of development
Figure 263: Spinal cord partnering deals by headline value
Figure 264: Spinal cord partnering deals by upfront payment
Figure 265: Spinal cord partnering deals by royalty rate
Figure 266: Spinal cord partnering deals 2009-2014 by most active companies
Figure 267: Pancreatic cancer: Partnering frequency 2009-2014
Figure 268: Pancreatic cancer most active dealmakers
Figure 269: Pancreatic cancer partnering deals by industry sector
Figure 270: Pancreatic cancer partnering deals by type
Figure 271: Pancreatic cancer partnering deals by technology type
Figure 272: Pancreatic cancer partnering deals by stage of development
Figure 273: Pancreatic cancer partnering deals by headline value
Figure 274: Pancreatic cancer partnering deals by upfront payment
Figure 275: Pancreatic cancer partnering deals by royalty rate
Figure 276: pancreatic cancer partnering deals 2009-2014 by most active companies
Figure 277: Cosmetics: Partnering frequency 2009-2014
Figure 278: Cosmetics most active dealmakers
Figure 279: Cosmetics partnering deals by industry sector
Figure 280: Cosmetics partnering deals by type
Figure 281: Cosmetics partnering deals by technology type
Figure 282: Cosmetics partnering deals by stage of development
Figure 283: Cosmetics partnering deals by headline value
Figure 284: Cosmetics partnering deals by upfront payment
Figure 285: Cosmetics partnering deals by royalty rate
Figure 286: Cosmetics partnering deals 2009-2014 by most active companies
Figure 287: Asthma: Partnering frequency 2009-2014
Figure 288: Asthma most active dealmakers
Figure 289: Asthma partnering deals by industry sector
Figure 290: Asthma partnering deals by type
Figure 291: Asthma partnering deals by technology type
Figure 292: Asthma partnering deals by stage of development
Figure 293: Asthma partnering deals by headline value
Figure 294: Asthma partnering deals by upfront payment
Figure 295: Asthma partnering deals by royalty rate
Figure 296: Asthma partnering deals 2009-2014 by most active companies
Figure 297: Congestive heart failure: Partnering frequency 2009-2014
Figure 298: Congestive heart failure most active dealmakers
Figure 299: Congestive heart failure partnering deals by industry sector
Figure 300: Congestive heart failure partnering deals by type
Figure 301: Congestive heart failure partnering deals by technology type
Figure 302: Congestive heart failure partnering deals by stage of development
Figure 303: Congestive heart failure partnering deals by headline value
Figure 304: Congestive heart failure partnering deals by upfront payment
Figure 305: Congestive heart failure partnering deals by royalty rate
Figure 306: Congestive heart failure partnering deals 2009-2014 by most active companies
Figure 307: Rare genetic disorders: Partnering frequency 2009-2014
Figure 308: Rare genetic disorders most active dealmakers
Figure 309: Rare genetic disorders partnering deals by industry sector
Figure 310: Rare genetic disorders partnering deals by type
Figure 311: Rare genetic disorders partnering deals by technology type
Figure 312: Rare genetic disorders partnering deals by stage of development
Figure 313: Rare genetic disorders partnering deals by headline value
Figure 314: Rare genetic disorders partnering deals by upfront payment
Figure 315: Rare genetic disorders partnering deals by royalty rate
Figure 316: Rare genetic disorders partnering deals 2009-2014 by most active companies
Figure 317: Malaria: Partnering frequency 2009-2014
Figure 318: Malaria most active dealmakers
Figure 319: Malaria partnering deals by industry sector
Figure 320: Malaria partnering deals by type
Figure 321: Malaria partnering deals by technology type
Figure 322: Malaria partnering deals by stage of development
Figure 323: Malaria partnering deals by headline value
Figure 324: Malaria partnering deals by upfront payment
Figure 325: Malaria partnering deals by royalty rate
Figure 326: Malaria partnering deals 2009-2014 by most active companies
Figure 327: Melanoma: Partnering frequency 2009-2014
Figure 328: Melanoma most active dealmakers
Figure 329: Melanoma partnering deals by industry sector
Figure 330: Melanoma partnering deals by type
Figure 331: Melanoma partnering deals by technology type
Figure 332: Melanoma partnering deals by stage of development
Figure 333: Melanoma partnering deals by headline value
Figure 334: Melanoma partnering deals by upfront payment
Figure 335: Melanoma partnering deals by royalty rate
Figure 336: Melanoma partnering deals 2009-2014 by most active companies
Figure 337: Brain cancer: Partnering frequency 2009-2014
Figure 338: Brain cancer most active dealmakers
Figure 339: Brain cancer partnering deals by industry sector
Figure 340: Brain cancer partnering deals by type
Figure 341: Brain cancer partnering deals by technology type
Figure 342: Brain cancer partnering deals by stage of development
Figure 343: Brain cancer partnering deals by headline value
Figure 344: Brain cancer partnering deals by upfront payment
Figure 345: Brain cancer partnering deals by royalty rate
Figure 346: Brain cancer partnering deals 2009-2014 by most active companies
Figure 347: Stroke: Partnering frequency 2009-2014
Figure 348: Stroke most active dealmakers
Figure 349: Stroke partnering deals by industry sector
Figure 350: Stroke partnering deals by type
Figure 351: Stroke partnering deals by technology type
Figure 352: Stroke artnering deals by stage of development
Figure 353: Stroke partnering deals by headline value
Figure 354: Stroke partnering deals by upfront payment
Figure 355: Stroke partnering deals by royalty rate
Figure 356: stroke partnering deals 2009-2014 by most active companies
Figure 357: Online partnering resources

Read the full report:
Trends in Therapeutic Partnering

https://www.reportbuyer.com/product/1593890/Trends-in-Therapeutic-Partnering.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
The Internet of Things (IoT) is going to require a new way of thinking and of developing software for speed, security and innovation. This requires IT leaders to balance business as usual while anticipating for the next market and technology trends. Cloud provides the right IT asset portfolio to help today’s IT leaders manage the old and prepare for the new. Today the cloud conversation is evolving from private and public to hybrid. This session will provide use cases and insights to reinforce the value of the network in helping organizations to maximize their company’s cloud experience.
IoT is still a vague buzzword for many people. In his session at Internet of @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, will discuss the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. The presentation will also discuss how IoT is perceived by investors and how venture capitalist access this space. Other topics to discuss are barriers to success, what is new, what is old, and what the future may hold.
Whether you're a startup or a 100 year old enterprise, the Internet of Things offers a variety of new capabilities for your business. IoT style solutions can help you get closer your customers, launch new product lines and take over an industry. Some companies are dipping their toes in, but many have already taken the plunge, all while dramatic new capabilities continue to emerge. In his session at Internet of @ThingsExpo, Reid Carlberg, Senior Director, Developer Evangelism at salesforce.com, to discuss real-world use cases, patterns and opportunities you can harness today.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
Noted IoT expert and researcher Joseph di Paolantonio (pictured below) has joined the @ThingsExpo faculty. Joseph, who describes himself as an “Independent Thinker” from DataArchon, will speak on the topic of “Smart Grids & Managing Big Utilities.” Over his career, Joseph di Paolantonio has worked in the energy, renewables, aerospace, telecommunications, and information technology industries. His expertise is in data analysis, system engineering, Bayesian statistics, data warehouses, business intelligence, data mining, predictive methods, and very large databases (VLDB). Prior to DataArcho...
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how thes...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) ir...
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn rea...
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder ...
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other mach...
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice s...
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehe...
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example...
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridsto...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changi...